FMP
Mainz Biomed B.V.
MYNZ
NASDAQ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
0.76 USD
-0.0259 (-3.41%)
About
ceo
Mr. Guido Baechler
sector
Healthcare
industry
Medical - Diagnostics & Research
website
https://mainzbiomed.com
exchange
NASDAQ
Description
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
CIK
0001874252
ISIN
NL0015000LC2
CUSIP
N5436L101
Address
Robert Koch Strasse 50
Phone
49 6131 554 2860
Country
DE
Employee
65
IPO Date
Nov 5, 2021
Key Executives
